Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Aker BioMarine ASA ( (DE:1PG) ).
Aker BioMarine reported a strong third quarter in 2025, with a 15% increase in revenue to USD 56.8 million and a 50% rise in adjusted EBITDA. The Human Health Ingredients segment showed significant growth, driven by increased demand and a favorable price mix, while Consumer Health Products experienced a slight decline in revenue. The company secured a new supply agreement for Superba Krill Oil, enhancing its market position. Aker BioMarine is focusing on cost efficiency and adapting to market trends amid macroeconomic uncertainties.
More about Aker BioMarine ASA
Aker BioMarine is a leading innovator in human health and nutrition, specializing in krill-derived products sourced from Antarctica. The company’s product portfolio includes Superba Krill Oil, Lysoveta, Revervia, PL+, and the consumer brand Kori Krill. Aker BioMarine is also involved in sustainability initiatives through its spin-offs AION and Understory, and is listed on the Oslo Stock Exchange.
Average Trading Volume: 23,643
Current Market Cap: NOK7.8B
See more insights into 1PG stock on TipRanks’ Stock Analysis page.